The Society of NeuroInterventional Surgery and M2S announced the launch of the NeuroVascular Quality Initiative, a multi-module registry system designed to track performance and outcomes data across a variety of neurovascular conditions. The launch debuts the Acute Ischaemic Stroke module, which will be used to track and benchmark clinical performance at the centre level and nationally, providing valuable insight into the effectiveness of endovascular interventions and associated devices in treating a condition known to be the nation’s fourth leading cause of death. The NeuroVascular Quality Initiative is now officially enrolling hospitals and specialists in the Acute Ischaemic Stroke module.
As neurointerventional procedures have changed the treatment landscape over the past two decades and offered thousands of patients quality treatment alternatives to traditional medical approaches, the NeuroVascular Quality Initiative is designed to track the success of these procedures, as well as demonstrate areas for improvement. Specifically, the NeuroVascular Quality Initiative will collect detailed data on:
- Patient demographics including age, weight/height, and co-morbidities
- Patient history including pre-operative medications, pre-stroke status and key time metrics associated to patient arrival and imaging
- Procedure details including treatments and devices used and medications given
- Follow-up including 14 day, 30 day, month and one year follow up
The NeuroVascular Quality Initiative will be governed by the Society of NeuroInterventional Surgery Patient Safety Organisation, which oversees the data sharing arrangements and patient safety initiatives conducted within the NeuroVascular Quality Initiative. The importance of the Patient Safety Organisation structure is that it protects all comparative analyses generated within the Patient Safety Organisation from legal discovery in state and federal court. Furthermore, it permits the collection of patient identified data for quality improvement purposes without requiring consent from individual patients or prior approval from an Institutional Review Board.
“By encouraging the collection, aggregation, benchmarking, and analysis of clinical data, the NeuroVascular Quality Initiative will assist Society of NeuroInterventional Surgery members in understanding and improving patient outcomes in a safe environment. The NeuroVascular Quality Initiative will also permit tracking of new devices and device efficacy in a real world setting which is a critical need within this evolving field,” says Peter Rasmussen, medical director of the Society of NeuroInterventional Surgery Patient Safety Organisation.
Looking forward, the Society of NeuroInterventional Surgery Patient Safety Organisation is already planning its next-stage launch of two modules dedicated to cerebral aneurysms and cerebral arteriovenous malformations, scheduled for later this year. Additional considerations for modules include diagnostic angiography and spinal disease.
